Shire PLC (SHP) Rating Reiterated by Credit Suisse Group
Credit Suisse Group reissued their outperform rating on shares of Shire PLC (LON:SHP) in a research note issued to investors on Friday. The brokerage currently has a GBX 5,350 ($69.67) price target on the biopharmaceutical company’s stock.
SHP has been the topic of several other research reports. Liberum Capital reissued a hold rating and issued a GBX 4,900 ($63.81) price target on shares of Shire PLC in a research report on Thursday, August 3rd. Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and set a GBX 6,800 ($88.55) target price on shares of Shire PLC in a report on Wednesday, April 12th. J P Morgan Chase & Co reaffirmed an overweight rating on shares of Shire PLC in a report on Tuesday, June 27th. Barclays PLC reissued an overweight rating and issued a GBX 6,300 ($82.04) price target on shares of Shire PLC in a research note on Tuesday, June 27th. Finally, Deutsche Bank AG reissued a buy rating and issued a GBX 6,300 ($82.04) price target on shares of Shire PLC in a research note on Wednesday, May 3rd. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of Buy and an average price target of GBX 5,937.29 ($77.32).
Shire PLC (LON:SHP) opened at 4016.00 on Friday. The company’s market capitalization is GBX 36.31 billion. The firm has a 50-day moving average of GBX 4,265.08 and a 200 day moving average of GBX 4,538.30. Shire PLC has a 12-month low of GBX 3,981.50 and a 12-month high of GBX 5,377.00.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/07/shire-plc-shp-rating-reiterated-by-credit-suisse-group.html.
In other news, insider Dominic Blakemore acquired 152 shares of Shire PLC stock in a transaction on Friday, June 30th. The stock was acquired at an average cost of GBX 4,255 ($55.41) per share, for a total transaction of £6,467.60 ($8,422.45).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.